Zero Candida Ltd (TSX-V:ZCT) recently highlighted its progress in developing an innovative AI-driven device for Candida treatment.
Founded in 2022, the company’s patented blue-light therapy offers a non-drug solution for treating yeast infections. The technology is designed to eliminate the fungus within hours while preserving the natural probiotics in the vaginal environment.
Candida infections are widespread, CEO, Eli Ben Haroosh noted, affecting 75% of women globally at least once.
“Current treatments like creams or pills can take weeks or months and often fail to prevent recurrence,” he told Proactive.
The company is advancing toward clinical trials, with Ben Haroosh explaining that preclinical safety studies using chimpanzees demonstrated 100% safety.
The final product design is expected to be completed by Q1 2025, with human trials involving 200 women set for Q3 2025.
Zero Candida also noted its recent listing on the TSX Venture Exchange under the ticker symbol ZCT, with shares trading above $2. The company plans to expand its reach by dual listing on the OTC in January 2025, followed by a listing on the Frankfurt Exchange.
Ben Haroosh emphasized the significant market potential, as recurring Candida infections are projected to impact 158 million women by 2030.
“Zero Candida won’t stop with Candida treatment,” Ben Haroosh said.
“We aim to introduce more innovations for women’s health in the future.”